Inventors list |
Assignees list |
Classification tree browser |
Top 100 Inventors |
Top 100 Assignees |
Hirohashi
Masaki Hirohashi, Kyoto JP
| Patent application number | Description | Published |
|---|---|---|
| 20090103007 | DIELECTRIC BARRIER DISCHARGE LAMP, BACKLIGHT DEVICE, AND LIQUID CRYSTAL DISPLAY DEVICE - A dielectric barrier discharge lamp | 04-23-2009 |
Mitsuji Hirohashi, Chiba JP
| Patent application number | Description | Published |
|---|---|---|
| 20090035171 | High-Strength And High-Toughness Magnesium Alloy And Method For Manufacturing Same - Provided is a high-strength and high-toughness magnesium alloy which has practical level of both the strength and the toughness for expanded applications of the magnesium alloys, and is a method for manufacturing thereof. The high-strength and high-toughness magnesium alloy of the present invention contains: a atom % in total of at least one metal of Cu, Ni, and Co; and b atom % in total of at least one element selected from the group consisting of Y, Dy, Er, Ho, Gd, Tb, and Tm, while a and b satisfying the following formulae (1) to (3), | 02-05-2009 |
Setsuo Hirohashi, Tokyo-To JP
| Patent application number | Description | Published |
|---|---|---|
| 20090004671 | Marker Protein For Use In Diagnosis Of Pancreatic Cancer - Disclosed herein are a pancreatic carcinoma marker protein that is a blood protein having a molecular weight of 28,080±15, 17,272±9, 17,253±9, 8,766±5, or 14,779±8 (m/z) and a method for detecting pancreatic carcinoma using the marker protein as an indicator. | 01-01-2009 |
| 20110112278 | NOVEL TUMOR MARKER FOR PANCREATIC CANCER - A novel protein and a fragment thereof useful as a tumor marker of pancreatic cancer are disclosed. This protein or a fragment thereof is a modified α-fibrinogen protein containing an oxidized amino acid residue(s) or a fragment thereof containing said oxidized amino acid residue(s). The oxidized amino acid residue(s) is one or more amino acid residues selected from the group consisting of (a) a proline residue corresponding to the proline residue at the position of 530 in SEQ ID NO: 2, and (b) a proline residue corresponding to the proline residue at the position of 565 in SEQ ID NO: 2. | 05-12-2011 |
Takuya Hirohashi, Kanagawa JP
| Patent application number | Description | Published |
|---|---|---|
| 20100294535 | LIGHT-TRANSMITTING CONDUCTIVE FILM, DISPLAY DEVICE, ELECTRONIC DEVICE, AND MANUFACTURING METHOD OF LIGHT-TRANSMITTING CONDUCTIVE FILM - An object is to provide a transparent conductive film having favorable transparency and conductivity at low cost. Another object is to reduce the resistivity of a transparent conductive film formed using conductive oxynitride including zinc and aluminum. Another object is to provide a transparent conductive film that is formed using conductive oxynitride including zinc and aluminum. When aluminum and nitrogen are made to be included in a transparent conductive film formed using oxide including zinc to form a transparent conductive film that is formed using conductive oxynitride including zinc and aluminum, the transparent conductive film can have reduced resistivity. Heat treatment after the formation of the transparent conductive film that is formed using conductive oxynitride including zinc and aluminum enables reduction in resistivity of the transparent conductive film. | 11-25-2010 |
Yoshihiko Hirohashi, Sapporo-Shi JP
| Patent application number | Description | Published |
|---|---|---|
| 20100034780 | TUMOR ANTIGEN PEPTIDE DERIVED FROM AMACR - The present invention relates to a peptide which comprises a partial peptide derived from AMACR and is capable of binding to an HLA antigen and is recognized by a CTL, and a pharmaceutical composition comprising the peptide and a pharmaceutically acceptable carrier, and the like. | 02-11-2010 |
Yoshihiko Hirohashi, Hokkaido JP
| Patent application number | Description | Published |
|---|---|---|
| 20100015101 | NOVEL TUMOR ANTIGEN PEPTIDES - The invention relates to novel tumor antigen proteins and peptides derived therefrom and use of the same in the filed of cancer immunity. Specifically, the inventions relates to a peptide which comprises a partial peptide derived from Lengsin, BJ-TSA-9, C20orf42, BUB1, C10orf3 or HIFPH3 and is capable of binding to an HLA antigen and is recognized by a CTL, and a pharmaceutical composition comprising the peptide and a pharmaceutically acceptable carrier. | 01-21-2010 |